OBJECTIVES: To describe demographic and clinical characteristics and real-world treatment patterns for post-menopausal patients with ER+/HER2- metastatic breast cancer (MBC) in the United Kingdom (UK). METHODS: We conducted a retrospective review of medical records from institutions across the UK. Records were eligible for abstraction if patients were post-menopausal, had ER+/HER2- MBC (stage IV), and had discontinued second-line treatment in the metastatic setting between 1/1/2008 and 3/1/2014. Patients who participated in clinical trials were excluded. This study was considered a "Service Evaluation" by National Research Ethical Service guidance, thus ethics review was not required. Patient demographic, clinical characteristics and treatment patterns including time to progression (TTP) and treatment discontinuation were assessed. RESULTS: Forty-one medical/ clinical oncologists provided information for 209 patients. Patients were aged 62 years on average and predominantly Caucasian (87%), with 68% diagnosed in metastatic stage and 32% progressed from earlier stages. Bone was the most common site of metastasis (66%) followed by lung/pleura (50%), liver (41%), and lymph nodes (35%). In the first-line MBC setting, 49% of patients received endocrine therapy alone, 6% received it in combination with chemotherapy, 15% received it following chemotherapy induction, and 30% received chemotherapy alone. Chemotherapy usage increased in subsequent therapy lines (33% in second-line [n=209]; 53% in third-line [n=116]). Disease progression was the primary reason for discontinuing treatment in both first- and second-line (60% and 68% respectively). During first-line treatment, 86% progressed, with median TTP of 9.5 months. In second-line, 79% progressed, with median TTP of 7 months. CONCLUSIONS: Endocrine therapy and chemotherapy were commonly prescribed for ER+/HER2- MBC patients. Disease progression remains the most common reason for stopping/ changing therapies, with median TTP < 1 year. These findings suggest that there is a continuing unmet need for new treatments that can extend TTP and address the potential limitations of current therapies.